FIELD: medicine, pharmaceutics.
SUBSTANCE: present invention refers to pharmaceutics, namely to a pharmaceutical composition (a solid oral dosage form (a tablet or a capsule)) of tyrosine kinase Bcr-Abl inhibitor - imatinib(4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)-pyrimidin-2-ylamino)phenyl]benzamide). The pharmaceutical composition contains 25-45 wt % of imatinib, preferentially imatinib mesylate, more preferentially an α-crystalline form of imatinib mesylate, a binding agent representing povidone, and at least two desintegrant representing low-substituted hydroxypropyl cellulose and sodium carboxymethyl starch.
EFFECT: invention provides the min 80% imatinib release from the tablet for 15 minutes after oral administration and enables extending the range of drugs used for leukaemia.
14 cl, 4 dwg, 3 tbl, 2 ex
Title | Year | Author | Number |
---|---|---|---|
PHARMACEUTICAL COMPOSITION FOR TREATING HIV INFECTION, METHOD FOR PREPARING IT, AND METHOD OF TREATING | 2012 |
|
RU2505286C1 |
PHARMACEUTICAL COMPOSITION OF FABOMOTIZOLE DIHYDROCHLORIDE | 2022 |
|
RU2828872C2 |
MEDICAL USE OF PYRROLOPYRIMIDINE COMPOUND AND SOLID PHARMACEUTICAL COMPOSITION OF PYRROLOPYRIMIDINE COMPOUND | 2019 |
|
RU2810112C2 |
SOLID PHARMACEUTICAL COMPOSITION CONTAINING TLR7 AGONIST | 2020 |
|
RU2822480C2 |
PHARMACEUTICAL PREPARATION | 2019 |
|
RU2756452C1 |
PHARMACEUTICAL COMPOSITIONS, CONTAINING IMATINIB AND RELEASE MODERATOR | 2006 |
|
RU2404775C2 |
PHARMACEUTICAL COMPOSITION | 2008 |
|
RU2470637C2 |
PHARMACEUTICAL COMPOSITION FOR TREATING HIV-INFECTION, METHOD FOR PREPARING AND METHOD OF USING | 2013 |
|
RU2543322C1 |
SOLID-PHASE LINEZOLID-CONTAINING PREPARATION | 2017 |
|
RU2690491C2 |
PHARMACEUTICAL COMPOSITION FOR ALLERGIC DISEASES | 2010 |
|
RU2453315C2 |
Authors
Dates
2014-05-27—Published
2012-08-22—Filed